ClinicalTrials.gg
CompletedNCT06592482Updated Feb 20, 2025

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

A Phase 1 interventional study of AZD0780 in Renal Impairment, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
14th of 29
30 · median 24
Started
2024
with 5 others
Phase 1
26 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 14th largest by enrollment, is one of 6 that started in 2024, is one of 26 in phase 1, and was the 21st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

This is a Phase I, multi-centre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD0780 in male and female participants (females of non-childbearing potential) with severe renal impairment not on dialysis, end-stage renal disease (ESRD) on intermittent haemodialysis (HD), or moderate renal impairment (optional) compared with male and female participants (females of non-childbearing potential) with normal renal function. Potential participants will be screened to assess their eligibility to enter the study up to 4 weeks prior to administration of study intervention. Eligible participants will be admitted to the study site on Day -1. On Day 1, an "A" single oral dose of AZD0780 will be administered, and participants will be confined to the study site until after assessments are completed on Day 11.

Read the detailed description

This is a Phase I, multi-centre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD0780 in male and female participants (females of non-childbearing potential) with severe renal impairment not on dialysis, end-stage renal disease (ESRD) on intermittent haemodialysis (HD), or moderate renal impairment (optional) compared with male and female participants (females of non-childbearing potential) with normal renal function.

Participants will be assigned to the following groups based on body surface area-adjusted estimated glomerular filtration rate (eGFR) determined by a local laboratory at screening by the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation (2021) using serum creatinine:

Group 1: Participants with severe renal impairment (eGFR \< 30 mL/min), not on dialysis.

Group 2: Participants with ESRD (eGFR \< 15 mL/min) on a stable intermittent HD schedule for at least 3 months prior to planned dosing.

Group 3: Participants with normal renal function demographically matched by sex,age, and body mass index (BMI) to the impaired participants (eGFR of ≥90 mL/min).

Group 4 (optional): Participants with moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min).

Initially, participants with severe renal impairment (Group 1) and ESRD (Group 2) will be enrolled, along with matching participants with normal renalfunction. An analysis of PK datamay be conducted to determine study progression. The decision to trigger the PK analysis and/or proceed with an evaluation of participants with moderate renal impairment (Group 4) will be made by the sponsor.

Each matched participant with normal renal function (Group 3) enrolled in the study will be demographically matched by sex, age (±10 years), and BMI (±20% kg/m2; data obtained at screening) to an enrolled renal impairment participant. Participants with normal renal function cannot be matched to more than one renally impaired participant within an impairment group; however, participants with normal renal function may be matched to 1 participant from more than 1 renal impairment group.

Potential participants will be screened to assess their eligibility to enter the study up to 4 weeks prior to administration of study intervention. Eligible participants will be admitted to the study site on Day -1. On Day 1, a "A" single oral dose of AZD0780 will be administered, and participants will be confined to the study site until after assessments are completed on Day 11.

For participants with ESRD (Group 2), the first post dose HD session should be scheduled to start 26 hours after administration of AZD0780. Subsequent HD sessions should be scheduled as clinically appropriate.

Serial PK (venous) blood samples will be collected up to 240 hours postdose and urine samples will be collected up to 96 hours postdose for the measurement of AZD0780. Urine collection is not required for participants who are anuric (ie, participants with ESRD on HD [Group 2]). For participants with ESRD (Group 2), blood samples for PK analysis will also be collected prior to, during, and at the end of HD. The entire dialysate will be collected in separate hourly collections on Day 2 for participants with ESRD (Group 2) for the measurement of AZD0780. The volume of each hourly collection of dialysate from which a sample is taken will be recorded. Physical examinations, 12-lead electrocardiograms, vital sign measurements, and clinical laboratory tests will be performed to assess safety and tolerability.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 85 years of age, inclusive at the time of signing ICF

For Participants with normal renal function:

  • Participant must be medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead ECGs, as deemed by the investigator at screening and Day -1

For Participants with renal impairment:

  • Diagnosis of chronic kidney disease, stable renal function in the 6 months prior to dosing
  • Received HD for chronic renal failure for at least 3 months prior to dosing (Group 2)
  • Participants with renal impairment, as follows, based on equation (BSA-adjusted eGFR) at screening: Group1 eGFR \< 30 mL/min), not requiring dialysis, Group 2 ESRD (eGFR \< 15 mL/min) on a stable intermittent HD schedule for at least 3 months prior to planned dosing and Group 4 (optional) moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min)
  • Male participants:
  • Males must be surgically sterile or using, in conjunction with their female partner, a highly effective method of for the duration of the study (from the time of study intervention administration) until 3 months after discharge to prevent pregnancy in a partner.
  • Female participants of non-:
  • Female participants must not be pregnant and must have a negative pregnancy test at screening and check-in, must not be lactating, and must not be of childbearing potential.

Exclusion criteria

Exclusion Criteria:

For Participants with normal renal function:

  • Any disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal including bone fractures, endocrine including adrenal insufficiency, metabolic, malignant, psychiatric, major physical impairment).
  • Use of any prescription or non-prescription drugs (including vitamins, recreational drugs, and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before study intervention, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.
  • History of any major surgical procedure within 30 days prior to study intervention.

For Participants with renal impairment:

  • Presence of unstable medical or psychological conditions which, in the opinion of the investigator, would compromise the participant's safety or successful participation in this study.
  • Renal transplant patients (participants on HD with non-functioning renal transplants are not excluded), participants waiting for organ transplant scheduled to occur during the study, and those with a history of acute kidney injury occurring within 3 months prior to screening.
  • History of any major surgical procedure within 30 days prior to study intervention.
  • Current or previous treatment with drugs for reduction or inhibition of PCSK9 (eg, evolocumab, alirocumab, or inclisiran).
  • Use of moderate/strong inhibitors or inducers of /5.
  • Unable to refrain from potassium binders, phosphate binders (eg, aluminium hydroxide and calcium carbonate), cholestyramine/colestipol, and ranitidine/nizatidine within 10 hours before and 10 hours after study intervention.
  • Receiving or has received within 14 days of screening, medication that contains a black box warning for significant . A list of prohibited medications can be found in protocol.
  • Use of concurrent medication which affects calculation of by affecting serum creatinine (eg, cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine, or quinine) within 7 days of Day -1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group 1: AZD0780

    Participants with severe renal impairment (eGFR \< 30 mL/min), not on dialysis.

    Drug: AZD0780

  • Experimental
    Group 2: AZD0780

    Participants with ESRD (eGFR \< 15 mL/min) on a stable intermittent HD schedule for at least 3 months prior to planned dosing.

    Drug: AZD0780

  • Experimental
    Group 3: AZD0780

    Participants with normal renal function demographically matched by sex, age, and body mass index (BMI) to the impaired participants (eGFR of ≥ 90 mL/min)

    Drug: AZD0780

  • Experimental
    Group 4 (optional): AZD0780

    Participants with moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min).

    Drug: AZD0780

Interventions

  • A single "A" dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water.

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under the concentration-time curve from zero to the last measurable concentration

    Time frame: From Day 1 to Day 11

  2. Cmax

    Maximum observed plasma concentration

    Time frame: From Day 1 to Day 11

  3. AUCinf

    Area under the concentration-time curve from zero to infinity

    Time frame: From Day 1 to Day 11

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of a single oral "A" dose for participants with severe renal impairment (not on dialysis), ESRD on HD, and moderate renal impairment (optional) and those with normal renal function

    Time frame: From Day 1 to Day 11

  2. Number of participants with abnormal vital signs, abnormal ECGs, and abnormal physical examination findings

    To assess the safety and tolerability of a single oral "A" dose for participants with severe renal impairment (not on dialysis), ESRD on HD, and moderate renal impairment (optional) and those with normal renal function

    Time frame: From Day 1 to Day 11

  3. Number of participants with abnormal laboratory test results

    To assess the safety and tolerability of a single oral "A" dose for participants with severe renal impairment (not on dialysis), ESRD on HD, and moderate renal impairment (optional) and those with normal renal function

    Time frame: From Day 1 to Day 11

  4. PK parameters Tmax

    Time to reach maximum observed plasma concentration

    Time frame: From Day 1 to Day 11

  5. PK parameters t1/2λz

    half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve

    Time frame: From Day 1 to Day 11

  6. PK parameters CL/F

    apparent total body clearance of drug from plasma after extravascular administration

    Time frame: From Day 1 to Day 11

  7. PK parameters CLNR/F

    Non-renal clearance of drug from plasma after oral administration

    Time frame: From Day 1 to Day 11

  8. PK parameters Vz/F

    Apparent volume of distribution during the terminal phase after extravascular administration

    Time frame: From Day 1 to Day 11

  9. PK parameters AUC0-96

    area under the concentration-time curve from zero to 96 hours postdose

    Time frame: From Day 1 to Day 11

  10. PK parameters CLr

    renal clearance of the drug from plasma

    Time frame: From Day 1 to Day 11

  11. PK parameters Ae

    cumulative amount of unchanged drug excreted into the urine

    Time frame: From Day 1 to Day 11

  12. PK parameters Fe

    Fraction of the drug excreted into the urine

    Time frame: From Day 1 to Day 11

07

Study locations

5 sites
  • Research Site
    Lake Forest, California 92630, United States
  • Research Site
    Hialeah, Florida 33014, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2024, 3 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Sep 19, 2024
StartActual
Aug 2, 2024
Primary completionActual
Dec 1, 2024
CompletionActual
Dec 1, 2024
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06592482
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 2, 2024
Primary completion
Dec 1, 2024
Completion
Dec 1, 2024
Last update
Feb 20, 2025

Study contacts

Kwabena Ayesu, Medicine
principal investigator · Omega Research Orlando
Thomas Marbury, Medicine
principal investigator · Orlando Clinical Research Center
Juan Carlos Rondon, Medicine
principal investigator · Clinical Pharmacology of Miami, Inc.
Trisha Shamp, Medicine
principal investigator · Nucleus Network
Joel Neutel, Medicine
principal investigator · Orange County Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion